The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors, Di Modugno, F., Mottolese M., Di Benedetto A., Conidi A., Novelli Flavia, Perracchio L., Venturo I., Botti C., Jager E., Santoni A., et al. , Clinical Cancer Research, Volume 12, Number 5, p.1470-1478, (2006)

Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems, Galeffi, Patrizia, Lombardi A., Pietraforte I., Novelli Flavia, Di Donato M., Sperandei M., Tornambé A., Fraioli R., Martayan A., Natali P.G., et al. , Journal of Translational Medicine, Volume 4, (2006)

Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: Multivariate analysis of prognostic factors, Nisticò, C., Cuppone F., Bria E., Fornier M., Giannarelli D., Mottolese M., Novelli Flavia, Natoli G., Cognetti F., and Terzoli E. , Anti-Cancer Drugs, Volume 17, Number 10, p.1193-1200, (2006)

Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy, Piperno, G., Cosimelli M., Donnorso R.P., Mancini R., Buglioni S., Novelli Flavia, Sperduti I., Zerbini V., Garufi C., and Mottolese M. , Journal of Chemotherapy, Volume 16, Number SUPPL. 5, p.11-14, (2004)

Plant and bacterial production of engineered antibodies for pharmacological use in oncology, Galeffi, Patrizia, Pietraforte Immacolata, Lombardi Alessio, Novelli Flavia, Sperandei Maria, and Cantale Cristina , Xth IAPTC&B Congress, Plant Biotechnology 2002 and Beyond, Orlando, Florida, USA, June 23-28,, (2002)